Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference112 articles.
1. PD-L1 expression: an emerging biomarker in non-small cell lung cancer;Adam;Ann. Pathol.,2016
2. A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker;Aguiar;Immunotherapy,2016
3. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial;Ahn;J. Thorac. Oncol.,2016
4. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013
5. Mutational signatures associated with tobacco smoking in human cancer;Alexandrov;Science,2016
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neural network models based on clinical characteristics for predicting immunotherapy efficacy in small cell lung cancer;Malignancy Spectrum;2024-08-04
2. Progress in research and treatment of immune checkpoints in breast cancer;Asia-Pacific Journal of Oncology;2024-04-08
3. Integrative Analysis of Prognostic Value and Immune Infiltration of ELOVL Gene Family in Lung Adenocarcinoma;2024-03-29
4. Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study;Frontiers in Oncology;2024-01-26
5. Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review;Cancer Treatment Reviews;2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3